10.09.25 -- Ivory Tower To CDMO: Universities Successfully Outsource Drug Development

Discover how Lonza's integrated CDMO model unites drug substance and drug product manufacturing to drive efficiency and quality. In this webinar, experts share real-world lessons from complex biologics programs, highlighting streamlined tech transfers, shared quality systems, and cross-functional collaboration. Learn how early alignment and proactive problem-solving accelerate timelines, ensure regulatory readiness, and deliver successful commercial outcomes. Click here to learn more.

Navigate the challenging path from concept to clinical reality by partnering with an experienced CDMO that can provide the expertise needed to move your therapeutic forward.

Discover how these devices offer solutions to the challenges of precise dosing, patient compliance, retention, and safety, uplifting the overall trial experience and providing real world insights.

Oxygen heterogeneity requires careful control for successful biopharma manufacturing and technology transfer. Unlock your production potential by mastering the distribution of oxygen.

Real-world examples have shown that, in some labs, manual screenings disappeared altogether, replaced by automated runs covering entire departments, saving time, multiplying output, and producing data sets robust enough to open new scientific doors.

With a growing interest in developing new and improved bioconjugate drugs, explore an “innovation through collaboration” approach that can facilitate access to next-generation conjugation technologies.

Learn how real-time monitoring with PAT enhances process control, shortens development timelines, and supports the shift toward continuous manufacturing in biopharmaceutical production.

Using the case study of afucosylated glycan levels, we highlight the impact of data-driven methodologies on improving process outcomes and ensuring high standards of quality and reliability.

While no two programs are alike, see how a customized approach to biologics development can overcome unique molecular challenges and accelerate your path to the clinic.

A major change in the regulatory framework for biosimilars is coming. Take proactive steps now to reduce development costs, accelerate approval, and unlock new opportunities in the shifting landscape.

Selecting a plunger stopper is key to de-risking the development and launch of biologic combination products — unearth how a new product influences exposure to extractables and leachables.

How do biopharma companies solve the common challenge of increasing output while decreasing headcount? Consider three options: temporary staffing, outsourcing, and insourcing.

This presentation highlights how simplified execution with development, filling, and analytics under one roof ensures safe, efficacious products reach patients in need.

Review real examples of how this outsourcing partner helps drug sponsors through transparency that empowers, integration that simplifies, methods that de-risk, and experience that accelerates.

You can count on our extensive scientific and manufacturing expertise, stringent quality standards, and highly responsive customer service to ensure timely delivery of your life-changing products.

Associate Director kojoX and Technology Development, Rasmus Petersen, presents a high-level overview of FDB’s capabilities, its global facilities network, and capacity updates for BIOLOGICS.